Citations

Clear

959 citation(s) found for "Service, F J".

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
Arnaldi, Dario , Mattioli, Pietro , Raffa, Stefano, Pardini, Matteo , Massa, Federico , Iranzo, Álex , Perissinotti, Andrés , Gaig, Carles , Serradell, Mónica , Muñoz‐Lopetegi, Amaia , Mayà, Gerard , Liguori, Claudio , Fernandes, Mariana , Miyagawa, Toji , Lowe, Val J. , Puligheddu, Monica , Serra, Alessandra , Hu, Michele T., Klein, Johannes , Bes, Frédérik , Kunz, Dieter , Verbizier, Delphine de, Kulcsárová, Kristína , Giuliani, Alessandro , Pagani, Marco , Group, International REM Sleep Behavior Disorder Study, Liguori, Claudio , Miyamoto, Tomoyuki , Kunz, Dieter , Antelmi, Elena , Terzaghi, Michele , Massa, Federico , Maya, Gerard , Puligheddu, Monica , Kulcsarova, Kristina , Mattioli, Pietro , Arnaldi, Dario , Niñerola‐Baizán, Aida , Gaig, Carles , Placidi, Fabio , Chiaravalloti, Agostino , Šonka, Karel , Dušek, Petr , Zogala, David , Trnka, Jiří , Boeve, Bradley F. , Miyamoto, Tomoyuki , Miyamoto, Masayuki , Figorilli, Michela , Hu, Michele T., Cochen De Cock, Valérie , Plazzi, Giuseppe , Antelmi, Elena , Bossert, Irene , Martino, Alessio , Nobili, Flavio Mariano , Morbelli, Silvia , Group, International REM Sleep Behavior Disorder Study

Mayo Clinic

Annals of Neurology | March 11, 2024 | Volume: 95 | Issue: 6 | Pages: 1178-1192

10.1002/ana.26902 | PMID 38466158 Get It

Objective To apply a machine learning analysis to clinical and presynaptic dopaminergic imaging data of patients with rapid eye movement (REM) sleep behavior disorder (RBD) to predict the development of Parkinson disease (PD) and dementia with Lewy bodies (DLB). Method s In this multicenter study of the International RBD study group, 173 patients (mean age 70.5 ± 6.3 years, 70.5% males) with polysomnography‐confirmed RBD who eventually phenoconverted to overt alpha‐synucleinopathy (RBD due to synucleinopathy) were enrolled, and underwent baseline presynaptic dopaminergic imaging and clinical assessment, including motor, cognitive, olfaction, and constipation evaluation. For comparison, 232 RBD non‐phenoconvertor patients (67.6 ± 7.1 years, 78.4% males) and 160 controls (68.2 ± 7.2 years, 53.1% males) were enrolled. Imaging and clinical features were analyzed by machine learning to determine predictors of phenoconversion. Results Machine learning analysis showed that clinical data alone poorly predicted phenoconversion. Presynaptic dopaminergic imaging significantly improved the prediction, especially in combination with clinical data, with 77% sensitivity and 85% specificity in differentiating RBD due to synucleinopathy from non phenoconverted RBD patients, and 85% sensitivity and 86% specificity in discriminating PD‐converters from DLB‐converters. Quantification of presynaptic dopaminergic imaging showed that an empirical z ‐score cutoff of −1.0 at the most affected hemisphere putamen characterized RBD due to synucleinopathy patients, while a cutoff of −1.0 at the most affected hemisphere putamen/caudate ratio characterized PD‐converters. Interpretation Clinical data alone poorly predicted phenoconversion in RBD due to synucleinopathy patients. Conversely, presynaptic dopaminergic imaging allows a good prediction of forthcoming phenoconversion diagnosis. This finding may be used in designing future disease‐modifying trials. ANN NEUROL 2024;95:1178–1192
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components
Wheeler, Allison P. , Snyder, Edward L. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Bentow, Stanley, Varrone, Jeanne, Fontaine, Magali , Fenelus, Maly , Jeng, Michael , Spencer, Bryan R , O'Brien, Jennifer J, Roback, John D , Avecilla, Scott T , Benjamin, Richard J , Cohn, Claudia S , Wheeler, Allison P , Nooka, Ajay K. , Spinella, Philip C. , Liles, Darla , Gehrie, Eric A , Spencer, Bryan R. , Johnson, Andrew, Liu, Kathy , Corash, Laurence M

Mayo Clinic

Blood Advances | March 6, 2024 | Volume: 8 | Issue: 9 | Pages: 2290-2299

10.1182/bloodadvances.2023012425 | PMID 38447116 Get It

Abstract Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen–reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of –1.5% (95% confidence interval [CI], –2.7 to –0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, –2.4%; 95% CI, –4.2 to –0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222.
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis
Midol, Charles , Wiebe, Edgar , Siegert, Elise , Huscher, Dörte , Béhal, Hélène, Matteson, Eric L. , Buttgereit, Frank , Sobanski, Vincent , Buttgereit, Frank , Sobanski, Vincent , Launay, David , Hachulla, É.

Mayo Clinic

Rheumatology | March 6, 2024 | Volume: 64 | Issue: 3 | Pages: 1270-1276

10.1093/rheumatology/keae142 | PMID 38452356 Get It

Abstract Objectives Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc. Methods This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy. Results A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04–1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18–4.16]) and treatment with GC (OR 4.48 [2.42–8.26]) were significantly and independently associated with OP. Conclusion Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152

10.1158/2643-3230.bcd-24-0022 | PMID 38441243 Get It

Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
Akhtar, Ayesha , Ijaz, Huda, Waseem, Maria , Saif, Yasir, Iqbal, Haris, Batool, Syeda Aasia , Khan, Aarash , Khan, Muhammad Ijaz , Kumari, Usha , Surani, Salim

Mayo Clinic

Annals of Medicine & Surgery | February 27, 2024 | Volume: 86 | Issue: 4 | Pages: 1929-1932

10.1097/ms9.0000000000001875 | PMID 38576946 Get It

Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is characterized by ectopic deposition of fat in the liver, in the absence of other secondary causes of fat buildup. The relationship between NAFLD, including alanine aminotransferase (ALT), and glycated haemoglobin (HbA1c), is important for predicting the severity of disease and prognosis. This study aims to investigate the association of HbA1c in type 2 diabetes mellitus (T2DM) patients with NAFLD via measuring the ALT levels. Materials and methods: This retrospective cross-sectional study enroled 130 patients with T2DM and NAFLD. The association between levels of HbA1c and ALT in patients of NAFLD with controlled and uncontrolled T2DM, respectively, was investigated. Stratification was done based on gender and diabetic control, using HbA1c levels as a marker of glycemic control. Serum ALT levels were also compared in both groups. Results: The mean age of the participants was 50.2±5.7 years. The total participants were 130, of which 77 (59.3%) were females and 53 (40.7%) were males. The numbers of patients having uncontrolled T2DM (HbA1c>7%), and controlled T2DM (HbA1c <7%) were 78 (60%) and 52 (40%), respectively. Moreover, 46 (35.3%) females and 32 (24.7%) males had uncontrolled T2DM, and 31 (23.8%) females and 21 (16.2%) males had controlled T2DM. The mean ALT level for uncontrolled and controlled T2DM in female patients was found to be 24.6±3.4 and 13.5±2.4, respectively, (P <0.05). For male patients, it was found to be 54.0±4.9 and 29.1±5.4, respectively (P=0.008). Conclusion: There is a positive association between elevated HbA1c and ALT levels in T2DM patients with NAFLD.
This is giving me a complex: a practical attempt to streamline nontuberculous mycobacteria nomenclature for clinical purposes
Wengenack, Nancy L. , Brown‐Elliott, Barbara A. , Parrish, Nicole , Salfinger, Max , Wallace, Richard J. , Zelazny, Adrian M. , Parrish, Nicole M , Turenne, Christine Y , Zelazny, Adrian M , Turenne, Christine Y.

Mayo Clinic

Journal of Clinical Microbiology | February 23, 2024 | Volume: 62 | Issue: 3 | Pages: No page available

10.1128/jcm.01531-23 | PMID 38393324 Get It

Characteristics of blood banking/transfusion medicine fellows in the United States, 2013–2021: Lessons learned from the Transfusion Medicine In‐Service Examination (TMISE) practice survey
Karafin, Matthew S. , Tanhehco, Yvette C. , Kreuter, Justin D.

Mayo Clinic

Transfusion | February 21, 2024 | Volume: 64 | Issue: 2 | Pages: 414-415

10.1111/trf.17705 | PMID 38379529 Get It

Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia
Peltenburg, Puck J. , Heuvel, Lieke M. van den , Kallas, Dania , Bell, Cheyanne , Denjoy, Isabelle , Behr, Elijah R. , Kammeraad, Janneke A.E. , Yap, Sing‐Chien , Probst, Vincent , Ackerman, Michael J. , Wilde, Arthur A.M. , van den Heuvel, Lieke M , Kammeraad, Janneke A E , Yap, Sing-Chien , Probst, Vincent , Ackerman, Michael J , Blom, Nico A , Wilde, Arthur A M , Clur, Sally-Ann B , van der Werf, Christian , Behr, Elijah Raphael , Denjoy, Isabelle , Peltenburg, Puck J , Field, Ella , Blom, Nico A. , Clur, Sally‐Ann B. , Werf, Christian van der

Mayo Clinic

Europace | February 13, 2024 | Volume: 26 | Issue: 2 | Pages: No page available

10.1093/europace/euae044 | PMID 38349347 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT. Methods and results An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22–50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3–12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6–31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1–1.3, P &lt; 0.001) were independently associated with non-adherence. Conclusion The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.
In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals
Iovleva, Alina , McElheny, Christi L. , Fowler, Erin L., Cober, Eric , Herc, Erica , Arias, César A. , Hill, Carol , Baum, Keri, Fowler, Vance G. , Chambers, Henry F. , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , van Duin, David , Bonomo, Robert A , Doi, Yohei , Hill, Carol , Arias, César A. , Fowler, Vance G. , Patel, Robin , Bonomo, Robert A. , Doi, Yohei

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 30, 2024 | Volume: 68 | Issue: 3 | Pages: No page available

10.1128/aac.01258-23 | PMID 38289078 Get It

ABSTRACT The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC 50 /MIC 90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.